Arca Biopharma (ABIO) has released an update to notify the public and investors about its officers.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
On January 30, 2024, ARCA biopharma, Inc.’s Board approved compensation for its non-employee directors under its Director Compensation Policy. Each director received options to purchase 6,000 shares at $1.64 per share, in line with the closing price on the Nasdaq on that day. These options, governed by the ARCA 2020 Equity Incentive Plan and standard agreements, will vest monthly over a year provided the directors continue their board service.
For further insights into ABIO corporate activity, check out TipRanks’ Insiders Trading Activity page.
For a comprehensive understanding of the announcement, you can read the full document here.